pdgfa Search Results


91
Proteintech antibodies for fus
Antibodies For Fus, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/TUSC2+Antibody/pmc06612190-77-26-29
Average 91 stars, based on 1 article reviews
antibodies for fus - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

92
Proteintech antibodies against pdap1
LINC00460 could directly bind with <t>PDAP1.</t> (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).
Antibodies Against Pdap1, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/PDAP1+Antibody/pmc09633316-116-7-11
Average 92 stars, based on 1 article reviews
antibodies against pdap1 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

91
Novus Biologicals recombinant mouse pdgfa
LINC00460 could directly bind with <t>PDAP1.</t> (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).
Recombinant Mouse Pdgfa, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Recombinant+Mouse+PDGFA+Protein/pm36635563-783-49-52
Average 91 stars, based on 1 article reviews
recombinant mouse pdgfa - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
MedChemExpress mouse medchemexpress
LINC00460 could directly bind with <t>PDAP1.</t> (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).
Mouse Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/PDGF-AA%2C+Mouse/pmc12209307__DataSheet1-12-21-22
Average 93 stars, based on 1 article reviews
mouse medchemexpress - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Proteintech pdgfα
LINC00460 could directly bind with <t>PDAP1.</t> (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).
Pdgfα, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Animal-free+Recombinant+Human+PDGFaa/pmc10469866-120-56-57
Average 93 stars, based on 1 article reviews
pdgfα - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene am100096 pdgf ab
LINC00460 could directly bind with <t>PDAP1.</t> (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).
Am100096 Pdgf Ab, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/PDGF+AA+(PDGFA)+(NM_002607)+Human+Recombinant+Protein/us10517861-619-67-65
Average 90 stars, based on 1 article reviews
am100096 pdgf ab - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
OriGene human pdgf a b
Figure 1. Immunohistochemistry for <t>PDGF-α</t> expression; (A and B) <t>Positive</t> <t>immunohistochemical</t> reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.
Human Pdgf A B, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/PDGF+AA+(PDGFA)+Rabbit+Polyclonal+Antibody/pm21249316-57-15-17
Average 90 stars, based on 1 article reviews
human pdgf a b - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
OriGene nck1 mouse sirna duplexes
Figure 1. Immunohistochemistry for <t>PDGF-α</t> expression; (A and B) <t>Positive</t> <t>immunohistochemical</t> reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.
Nck1 Mouse Sirna Duplexes, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Pdgfa+Mouse+siRNA+Oligo+Duplex/pmc06137712__mmc1-60-41-35
Average 90 stars, based on 1 article reviews
nck1 mouse sirna duplexes - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Shanghai Korain Biotech Co Ltd rat enzyme linked immunosorbent assay elisa kit
Figure 1. Immunohistochemistry for <t>PDGF-α</t> expression; (A and B) <t>Positive</t> <t>immunohistochemical</t> reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.
Rat Enzyme Linked Immunosorbent Assay Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Rabbit+Platelet-derived+Growth+Factor+Subunit+A/10__56338_slash_jphp__v6i3__11226-85-9-15
Average 93 stars, based on 1 article reviews
rat enzyme linked immunosorbent assay elisa kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Novus Biologicals pdgf a
Figure 1. Immunohistochemistry for <t>PDGF-α</t> expression; (A and B) <t>Positive</t> <t>immunohistochemical</t> reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.
Pdgf A, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/PDGFA+Antibody+(MM0013-6D35)+%5BAllophycocyanin%5D/pm25686533-35-8-12
Average 86 stars, based on 1 article reviews
pdgf a - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
Thermo Fisher gene exp pdgfa hs00964426 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Hs00964426 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Gene+Exp%2E+PDGFA%2C+Hs00964426_m1/pmc06039566-295-33-7
Average 97 stars, based on 1 article reviews
gene exp pdgfa hs00964426 m1 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

85
Thermo Fisher gene exp pdgfa mm00435540 m1
Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A <t>(PDGFA)</t> , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005
Gene Exp Pdgfa Mm00435540 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfa/Gene+Exp%2E+Pdgfa%2C+Mm00435540_m1/pm28330949-84-47-48
Average 85 stars, based on 1 article reviews
gene exp pdgfa mm00435540 m1 - by Bioz Stars, 2026-11
85/100 stars
  Buy from Supplier

Image Search Results


LINC00460 could directly bind with PDAP1. (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).

Journal: Cancer Science

Article Title: Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460

doi: 10.1111/cas.15547

Figure Lengend Snippet: LINC00460 could directly bind with PDAP1. (A) FISH assay showed the sub‐cellular location of LINC00460 in CFPAC‐1. (U6: nucleus location positive control, 18S: cytoplasm control) The subcellular location of LINC00460 is mainly in cytoplasm, followed by the nucleus. (B) LINC00460 expression in the nucleus and cytoplasm fractions by qRT‐PCR were consistent with FISH results. Data from three independent experiments were expressed as mean ± SD. (C) RNA‐pull‐down‐MS results showed 291 proteins have the possibility of binding to LINC00460 in the intersection of three PDAC cell lines. (D) Volcano plot of RNA‐pull‐down‐MS revealed that PDAP1 (Log 10 [iBAQ] = 9.10) interacts with LINC00460. The red font indicates PDAP1. (E) RNA immunoprecipitation (RIP)‐qPCR assay detects the coupling of PDAP1 and LINC00460. (F) Predicted structure of the LINC00460 determined by RNAfold software and the prediction of LINC00460/PDAP1 interaction probabilities using RPIseq website. (G) Immunoblot of PDAP1 in RNA pull‐down extracts with different LINC00460 fragment sequences (1–237, 238–747, and 748–913).

Article Snippet: Thereafter, immunoblottings were performed with below primary antibodies against PDAP1 (#15081‐1‐AP, Proteintech), PDGFA (#203911, Abcam), PDGFR (#32570, Abcam), a PDGFR Activation Antibody Sampler Kit (#12651, CST), β‐actin (#4970, CST), and GAPDH (#60004‐1‐Ig, Proteintech) in TBST buffer containing 5% BSA overnight.

Techniques: Positive Control, Control, Expressing, Quantitative RT-PCR, Binding Assay, RNA Immunoprecipitation, Software, Western Blot

LINC00460 could regulate the proliferation of CAFs via the PDAP1/PDGFA/PDGFR pathway. (A) qRT‐PCR assay detected the mRNA level of PDAP1 and PDGFA after transduced LINC00460 shRNAs. (B) Western blot assay detected the protein level of PDAP1 and PDGFA after transduced LINC00460 shRNAs. (C) The concentration of PDGFA in the medium supernatant of CFAPC‐1 and PANC‐1 after silencing LINC00460 was measured by ELISA assay; values represent means ± SD of six replicate samples in each group. (D) Western blot assay validated KO‐PDAP1 cell lines. (E) Western blot assay showed the expression level of PDGFA in PANC‐1 cell line (KO‐PDAP1) after transduction of LINC00460 shRNAs. (F) ELISA assay showed the concentration of PDGFA in medium supernatant of PANC‐1 cell line (KO‐PDAP1) after transduction of LINC00460 shRNAs. Values represent means ± SD of six replicate samples in each group. (G) Western blot assay showed PDGFR‐β expression in eight pairs of PDAC CAFs and tumor cells. (H) Cell viability showed the different proliferation rate of CAFs after co‐cultured with the supernatant of CFPAC‐1 and PANC‐1. (I) Cell viability showed that crenolanib can reverse the proliferation of CAFs caused by silencing LINC00460. (J) Western blot analysis of the PDGFR‐β pathway activated genes in after transduced LIINC00460 shRNAs whose co‐cultured with CFPAC‐1 or PANC‐1 supernatant. (K) Western blot shows crenolanib can reverse PDGFR‐β pathway activation.

Journal: Cancer Science

Article Title: Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460

doi: 10.1111/cas.15547

Figure Lengend Snippet: LINC00460 could regulate the proliferation of CAFs via the PDAP1/PDGFA/PDGFR pathway. (A) qRT‐PCR assay detected the mRNA level of PDAP1 and PDGFA after transduced LINC00460 shRNAs. (B) Western blot assay detected the protein level of PDAP1 and PDGFA after transduced LINC00460 shRNAs. (C) The concentration of PDGFA in the medium supernatant of CFAPC‐1 and PANC‐1 after silencing LINC00460 was measured by ELISA assay; values represent means ± SD of six replicate samples in each group. (D) Western blot assay validated KO‐PDAP1 cell lines. (E) Western blot assay showed the expression level of PDGFA in PANC‐1 cell line (KO‐PDAP1) after transduction of LINC00460 shRNAs. (F) ELISA assay showed the concentration of PDGFA in medium supernatant of PANC‐1 cell line (KO‐PDAP1) after transduction of LINC00460 shRNAs. Values represent means ± SD of six replicate samples in each group. (G) Western blot assay showed PDGFR‐β expression in eight pairs of PDAC CAFs and tumor cells. (H) Cell viability showed the different proliferation rate of CAFs after co‐cultured with the supernatant of CFPAC‐1 and PANC‐1. (I) Cell viability showed that crenolanib can reverse the proliferation of CAFs caused by silencing LINC00460. (J) Western blot analysis of the PDGFR‐β pathway activated genes in after transduced LIINC00460 shRNAs whose co‐cultured with CFPAC‐1 or PANC‐1 supernatant. (K) Western blot shows crenolanib can reverse PDGFR‐β pathway activation.

Article Snippet: Thereafter, immunoblottings were performed with below primary antibodies against PDAP1 (#15081‐1‐AP, Proteintech), PDGFA (#203911, Abcam), PDGFR (#32570, Abcam), a PDGFR Activation Antibody Sampler Kit (#12651, CST), β‐actin (#4970, CST), and GAPDH (#60004‐1‐Ig, Proteintech) in TBST buffer containing 5% BSA overnight.

Techniques: Quantitative RT-PCR, Western Blot, Concentration Assay, Enzyme-linked Immunosorbent Assay, Expressing, Transduction, Cell Culture, Activation Assay

Proposed schematic model illustrating the interaction between LINC00460 and PDAP1, leading to the increase of CAF proliferation, which could cause chemotherapy resistance.

Journal: Cancer Science

Article Title: Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460

doi: 10.1111/cas.15547

Figure Lengend Snippet: Proposed schematic model illustrating the interaction between LINC00460 and PDAP1, leading to the increase of CAF proliferation, which could cause chemotherapy resistance.

Article Snippet: Thereafter, immunoblottings were performed with below primary antibodies against PDAP1 (#15081‐1‐AP, Proteintech), PDGFA (#203911, Abcam), PDGFR (#32570, Abcam), a PDGFR Activation Antibody Sampler Kit (#12651, CST), β‐actin (#4970, CST), and GAPDH (#60004‐1‐Ig, Proteintech) in TBST buffer containing 5% BSA overnight.

Techniques:

Figure 1. Immunohistochemistry for PDGF-α expression; (A and B) Positive immunohistochemical reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.

Journal: International journal of oncology

Article Title: Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.

doi: 10.3892/ijo.2011.912

Figure Lengend Snippet: Figure 1. Immunohistochemistry for PDGF-α expression; (A and B) Positive immunohistochemical reactivity against PDGF-α (x20) after incubation with carboplatin and imatinib (3+18 µmol) after 48 h. (C and D) Positive immunohistochemical reactivity against PDGF-α (x20-40) with carboplatin and imatinib (7.5+30 µmol) after 120 h. (E-F) Control group with strong immunoreactivity.

Article Snippet: Immunohistochemistry of PDGF-A/B ligand. immunohistochemical studies were performed using a monoclonal rabbit antibody directed against human PDGF-A/B (ACRIS Antibodies, Herford, Germany).

Techniques: Immunohistochemistry, Expressing, Immunohistochemical staining, Incubation, Control

Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Fibroblasts proliferation was analyzed after 2, 4, and 6 days of culture ( a–d ). We cultured fibroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and we observed decreased fibroblast proliferation after 4 and 6 days in a dose-dependent manner ( a ). Fibroblasts were cultured in the presence of platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) ( b ), basic fibroblast growth factor (FGFb, 10 ng/mL),( c) or vascular endothelial growth factor A (VEGF-A, 50 ng/mL) ( d ) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF ( e ). Representative images of this assay are shown in ( f ). Nintedanib treatment at 0.4 μM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 ( ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) ( g ). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically significant reduction of collagen type I alpha 1 chain (COL1A1) , collagen type III alpha 1 chain (COL3A1) , fibronectin 1 ( FN1) , platelet-derived growth factor A (PDGFA) , connective tissue growth factor (CTGF) , transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars) analyzed by qPCR ( h ). Data are expressed as means ± SD. N = 3 per group. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Cell Culture, Derivative Assay, Migration, Wound Healing Assay, Expressing, Produced, Control

Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Journal: Cell Death & Disease

Article Title: Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

doi: 10.1038/s41419-018-0792-6

Figure Lengend Snippet: Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain ( Col3a1 ), Fibronectin 1 ( Fn1 ), Platelet-derived growth factor A ( Pdgfa ), Platelet-derived growth factor B ( Pdgfb ), Connective tissue growth factor ( Ctgf ), Transforming growth factor beta 1 ( Tgfβ1 ), and Adhesion G protein-coupled receptor E1 ( Adgre1 ) showed changes in relative abundance following nintedanib in quadriceps ( a–h ), diaphragm ( i–p ), and tibialis anterior ( q–y ). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in mdx mice compared with WT . Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n = 5, mdx mice (mdx), n = 5; nintedanib-treated mdx mice (mdx + Ninte), n = 7. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: All mRNA-specific FAM-labeled primers/probe were purchased from Applied Biosystems and detected cDNA from the following genes: Ctgf (Mm01192933_g1), Pdgfa (Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1 (Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1 (Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1 (Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF (Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1 (Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), FN1 (Hs01549976_m1), ACTA (Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2 (Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1 (Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1), TP53 (Hs01034249_m1).

Techniques: Derivative Assay, Gene Expression, Expressing, Muscles